Lenvatinib
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Lenvatinib: From Thyroid Cancer to Liposarcoma
One-Sentence Summary
Lenvatinib is a multi-target tyrosine kinase inhibitor originally developed for thyroid cancer and later extended to hepatocellular and renal cell carcinoma. The TxGNN model predicts it may be effective for Liposarcoma, most notably in combination with eribulin, with 1 completed clinical trial and 4 supporting publications currently backing this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Thyroid cancer (differentiated thyroid carcinoma) — no New Zealand license record on file to confirm official indication text |
| Predicted New Indication | Liposarcoma |
| TxGNN Prediction Score | 99.51% |
| Evidence Level | L2 |
| New Zealand Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed original mechanism-of-action documentation for this candidate is a flagged data gap. Based on known information drawn from the evidence pack's own rationale, Lenvatinib is a multi-target tyrosine kinase inhibitor acting on VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET, giving it a broad anti-angiogenic effect that underlies its established use in vascular-dependent solid tumors such as thyroid, hepatocellular, and renal cell carcinoma.
Liposarcoma and leiomyosarcoma are soft-tissue sarcomas with rich tumor vasculature and stroma, making them mechanistically plausible targets for an anti-angiogenic agent. The strongest evidence here is not for Lenvatinib monotherapy but for the combination of Lenvatinib with eribulin (a microtubule inhibitor), where the two agents act through complementary mechanisms — anti-angiogenesis plus mitotic disruption.
This mechanistic complementarity is further supported by biomarker research showing CDK4 amplification as a recurring molecular feature of dedifferentiated liposarcoma, offering a potential basis for future biomarker-guided patient selection. Overall, the rationale is reasonable but is specific to the Lenvatinib+eribulin combination rather than Lenvatinib used alone.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03526679 | Phase 1/2 | Completed | 30 | Single-arm study of Lenvatinib (anti-angiogenic) plus eribulin (chemotherapy targeting mitosis) in inoperable/metastatic adipocytic sarcoma and leiomyosarcoma; relevance graded A — direct evaluation of the combination in advanced liposarcoma with completed enrollment |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36129471 | 2022 | Phase 1/2 (single-arm) | Clinical Cancer Research | Primary publication of the LEADER study (NCT03526679) reporting safety and efficacy of lenvatinib plus eribulin in advanced liposarcoma and leiomyosarcoma |
| 39103896 | 2024 | Preclinical/Biomarker | Experimental Hematology & Oncology | CDK4 identified as a prognostic biomarker in soft tissue sarcoma, with synergistic effect of CDK4 inhibition in sequential treatment of dedifferentiated liposarcoma |
| 29848686 | 2018 | Preclinical | Anticancer Research | Broad-spectrum preclinical activity of eribulin in combination with mechanistically different anticancer agents, including anti-angiogenic agents, across tumor models including liposarcoma |
| 34326745 | 2021 | Case Report | Case Reports in Oncology | Individualized treatment (targeted therapy + surgery + chemotherapy) achieved notable tumor size reduction in a dedifferentiated liposarcoma patient with lung/abdominal metastasis |
New Zealand Market Information
Lenvatinib is currently not marketed in New Zealand — no product licenses are on file (total authorizations: 0).
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (multi-target tyrosine kinase inhibitor; not a conventional cytotoxic chemotherapy agent) |
| Myelosuppression Risk | Not available in current data set; please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Not available in current data set; please refer to the package insert warnings and precautions |
| Monitoring Items | Not specified in current data set; TKI-class agents typically require monitoring of blood pressure, renal/hepatic function, thyroid function, and proteinuria — please refer to the package insert |
| Handling Protection | Not available in current data set; please refer to the package insert and institutional hazardous drug handling protocols |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A completed Phase 1/2 trial (n=30) plus four supporting publications establish a reasonable, though combination-specific (Lenvatinib+eribulin), rationale for liposarcoma — sufficient to advance under guardrails, but not sufficient to bypass a formal safety review, since New Zealand-specific labeling data (TFDA-equivalent warnings/contraindications) is a Blocking data gap that currently prevents entry into the S1 safety initial assessment.
To proceed, the following is needed:
- Package insert warnings, contraindications, and drug interaction data (currently a Blocking data gap)
- Confirmed original mechanism-of-action documentation (currently a High-severity data gap)
- Clarification that predicted efficacy applies to the Lenvatinib+eribulin combination, not Lenvatinib monotherapy
- Regulatory pathway assessment given the drug is not currently marketed in New Zealand
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.